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Case presentation
A 55-year-old architect was referred to the Basel University Hyper-
tension Clinic for evaluation of a 17-year history of high blood pressure
in the range of 170—190/100—120 mm Hg. Antihypertensive treatment—
including thiazide diuretics, beta blockers, alpha-methyldopa, and(early in the course) guanethidine and reserpine given alone or in
combination—caused unwanted effects such as daytime fatigue, dry
mouth, and impotence. The side effects interfered considerably with his
quality of life.
The family history was positive for hypertension. The patient had had
3 episodes of urinary tract infection but had no demonstrable abnor-
mality by rapid-sequence intravenous pyelogram. He suffered often
from pounding headaches, particularly during stress, but no palpita-
tions, sweating, ororthostatic falls in blood pressure were observed. He
had no additional cardiovascular risk factors: He had stopped smoking
7 years earlier, glucose tolerance was normal, and plasma cholesterol
concentrations were below 6.5 mmol/liter. Body weight was 68 kg;
height was 172 cm.
Eight weeks following discontinuation of all antihypertensive medi-
cations, the blood pressure was 180/110 mm Hg with the patient seated.
Physical examination showed evidence of an enlarged left ventricle, a
grade li/Ill systolic ejection murmur, and a third heart sound. An
electrocardiogram revealed left ventricular hypertrophy, and a plain
chest film disclosed a cardiothoracic ratio of 0.6, the cardiac diameter
being 15.5 cm. Laboratory evaluation revealed a serum potassium of 3.3
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mmol/liter, a low plasma renin activity of 0.5 ng/ml/hr with the patient
ingesting a reduced-sodium diet, and a 24-hour urinary sodium excre-
tion of 72 mmol. His usual diet included a high sodium intake, as
reflected by a daily sodium excretion rate of 237 mmol and a slightly
elevated aldosterone concentration (30 pg/dl) and aldosterone excretion
rate (28 tg/day). This hormonal profile suggested low-renin essential
hypertension. The possibility of pseudo-primary aldosteronism was
unlikely because repeated aldosterone measurements were never
higher, the diurnal pattern was normal, and 125J cholesterol adrenal
scintigraphy revealed no evidence of bilateral adrenal hyperplasia. The
serum creatinine was 1 mg/dl, and urinalysis was normal. Plasma
catecholamines as well as vanillylmandelic acid excretion rates were
within normal limits. Based on these results, a secondary form of
hypertension was ruled out.
Because of the well-documented responsiveness of low-renin, essen-
tial hypertension to diuretic therapy, the patient was given a daily
combination of 25 mg hydrochiorothiazide and 25 mg spironolactone.
These agents lowered the blood pressure to 160/95 mm Hg; blood
pressures below 150/90 mm Hg were reached only when the dose of
spironolactone was doubled. During the next 9 months of excellent
blood pressure control, the patient complained of fatigue, impotence,
and gynecomastia with painful nipples. These complaints necessitated a
change to other potassium-sparing diuretics containing amiloride or
triamterene. The gynecomastia disappeared within 3 months. These
alternatives, however, were less effective in controlling the blood
pressure despite his receiving maximal dosages; ultimately, the regimen
led to hypokalemia; impotence persisted.
Mainly because of the unwanted drug effects, the patient's medica-
tion was changed to slow-release verapamil, 240 mg, one tablet in the
morning and half a tablet in the evening. The blood pressure fell and
remained at 140/85mm Hg. Because of mild constipation during chronic
therapy with verapamil, the 1,4-dihydropyridine calcium antagonist
nitrendipine, 20 mg twice daily, was given; it produced equally good
blood pressure control without unwanted side effects. The changeover
from a diuretic to a calcium antagonist also was recognized by the
patient's wife, who soon called us and asked what we had done to
restore her husband's potency; we were unable to infer whether she
was complaining or thankful!
Discussion
PROFESSOR FRITZ R. BUHLER (Professor of Cardiology and
Medicine, Division of Cardiology, Departments of Medicine
and Research, University Hospital, Base!, Switzerland): Twen-
ty-five years ago, the calcium antagonist verapamil was shown
by Heidland to lower blood pressure acutely in patients with
hypertension and renal disease, although no effect was seen in
normotensive patients with renal-parenchymal disease or in
normal individuals following the intravenous administration of
the drug [11. All three groups manifested a comparable increase
in renal blood flow. Enhanced renal blood flow was the focus of
that report, and the observed antihypertensive response was
not commented on. In the late 1960s and early 1970s, the
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antihypertensive effectiveness of both verapamil [2, 3] and
nifedipine [4, 5] was documented; the fall in blood pressure was
greater in patients with higher pretreatment pressures [3]. In
1979, one study detected better antihypertensive efficacy of
calcium antagonists in black patients [6], who frequently have
low plasma renin activity [7]. By the end of the 1970s, reports of
long-term administration of calcium antagonists in hypertension
appeared [8—10]; these agents are now in widespread use. In the
last several years, convincing evidence has been adduced that
calcium antagonists are useful in long-term therapy [11—13].
These studies have coincided with the introduction of patho-
physiologic concepts that link derangements in transmembrane
sodium and calcium transport to the pathophysiology of essen-
tial hypertension [14, 15].
Essential hypertension: Cardiovascular and renal adaptation
Essential hypertension is characterized by several develop-
mental phases. In an early phase, beta-adrenoceptor-mediated
cardiovascular responses to physiologic or pharmacologic stim-
uli such as heart rate [16, 17], exercise tachycardia [16], and
hence cardiac output, as well as plasma renin activity [18] and
renin responsiveness [19—21] are augmented; renovascular re-
sistance is practically normal [22]. In a later phase of hyperten-
sion (the "established" phase) or with advanced age, beta-
adrenoceptor-mediated effects tend to be blunted (Fig. 1).
Accordingly, exercise-induced tachycardia and heart rate re-
sponses to isoproterenol are reduced [16, 23, 24], plasma renin
activity is normal or low [7, 18] and is hyperresponsive to
sympathetic stimuli [19, 25], and peripheral vasodilator re-
sponses to beta-adrenoceptor stimulation are diminished [26,
27]. Isoproterenol causes a lesser increase in renal blood flow of
older individuals and in patients with low-renin hypertension
[28]. With blunting of beta-adrenoceptor-mediated cardiovascu-
lar functions, alpha-adrenoceptor-mediated vasoconstriction
prevails. Hence the established phase of essential hypertension
is characterized by an elevated peripheral vascular resistance to
which enhanced post-junctional alpha-i- and alpha-2-adreno-
ceptor-mediated [29, 30] and calcium-influx-dependent [31]
vasoconstriction contribute. Increased calcium-influx-depen-
dent vasoconstriction may operate to a great extent through
postjunctional alpha-i- and alpha-2-adrenoceptors; this in-
crease in calcium influx eventually leads to increased intra-
cellular free-calcium concentration in vascular smooth muscle
cells. This influx also appears to be reflected by an increased
calcium concentration in platelets of patients with essential
hypertension. More important, the enhanced calcium influx is
correlated with the height of blood pressure [32] (Fig. 2A).
Decreased beta-adrenoceptor-mediated function in the later
phase of essential hypertension appears not to be the result of a
change in receptor number or affinity [33, 34] and therefore is
more likely due to alterations distal to the receptor site, for
example, at the level of the G protein coupling.
This transition from an early phase of essential hypertension,
in which beta-adrenoceptor-mediated functions prevail, to a
later one, dominated by alpha-adrenoceptor-mediated and cal-
cium-influx-dependent vasoconstriction, is characteristic of
low-renin essential hypertension, as exemplified by the patient
described here. These derangements correlate with several
other known features of low-renin essential hypertension, par-
Age
Fig. 1. Adrenergic and angiotensinergic regulation of the circulation.
Age, salt, and blood pressure per se contribute to the transition from a
predominantly hyper-beta-adrenoceptor-mediated cardiovascular regu-
lation in younger patients to a later maintenance phase (older patients),
in which beta effects and renin are blunted and alpha-adrenoceptor-
mediated vasoconstriction prevails. (From BUhler FR: Age and cardio-
vascular response adaptation. Determination of an antihypertensive
treatment concept primarily based on beta blockers and calcium entry
blockers. Hypertension 5 (suppl 1II):11194—IHl00, 1983.)
ticularly in the kidney, and some of them can be considered as
representing an acceleration of the normal aging process.
With increasing age, renal blood flow and GFR decrease. The
associated increase in filtration fraction [35, 36], that is, the
lower ratio of pre- and postglomerular resistances, eventually
leads to a rise in hydraulic pressure in the glomerular capillary.
Because of increased glomerular ultrafiltration and a reduction
in peritubular flow, proximal tubular sodium reabsorption in-
creases, mediated in part by alpha-2-adrenoceptors [37]. If
essential hypertension is characterized by a systemic plasma
membrane defect [381, it is conceivable that increased alpha-
2-adrenoceptor-mediated slow calcium channel influx, which
leads to increased cytosolic calcium, as well as blunted cal-
modulin-dependent Ca2-ATPase-fueled calcium extrusion (as
seen in platelets [39]), are operative in renal tubular cells and
that in such cells calcium influx is also accessible to calcium
entry blockade [40].
The disproportionate increase in plasma aldosterone relative
to the low plasma renin that occurs with aging and that is seen
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in patients with low-renin essential hypertension [41] might
contribute further to sodium retention via increased sodium
reabsorption in the distal and collecting tubule. Except for the
observations that cardiopulmonary volume is slightly increased
and that atrial natriuretic peptide is elevated, it is difficult to
demonstrate overt volume expansion in low-renin essential
hypertension [42, 43]. However, the resulting pressure natriure-
sis might have an offsetting effect, thus restoring volume toward
normal. Indeed, cardiovascular and renal regulatory as well as
counterregulatory mechanisms must be borne in mind when one
considers the mode of action and role of calcium antagonists in
the treatment of patients with different forms of hypertension.
Calcium antagonists: Cardiovascular action
Increased systemic vascular resistance in essential hyperten-
sion depends on increased calcium influx [31, 44]. Calcium
antagonists, which are potent arteriolar vasodilators, lower
cytolic free-calcium concentrations (Fig. 2B), mainly through a
reduction of transmembrane calcium influx. Infusion of vera-
pamil into the brachial artery produces vasodilation, as as-
sessed by venous occlusion plethysmography [31]. In this
study, the maximal vasodilatory responses of the forearm
circulation were inversely related to the patients' plasma renin
activity and angiotensin II concentration (Fig. 3). This relation-
ship suggests that a greater degree of calcium-influx-dependent
vasoconstriction occurs when the renin-angiotensin pressor
system is suppressed.
Acute and chronic antihypertensive drug effects differ with
respect to the underlying pathophysiologic mechanisms. Effects
also vary among the various types of calcium antagonists. Thus,
sublingual nifedipine administration in patients with essential
hypertension produces a modest, yet significant, acute reduc-
tion of systolic and diastolic blood pressure [45]. This decrease
is associated with increases in heart rate, cardiac index, plasma
norepinephrine concentrations, and plasma renin activity,
whereas calculated systemic vascular resistance decreases.
These findings suggest that arterial vasodilation reflexly medi-
ates sympathoneural activation. For a given stimulus, sympa-
thetic stimulation will be greater in individuals with normally
functioning baroreflexes.
Hypertension leads to a blunting of arterial baroreflex sensi-
tivity [46], as does advanced age [47]. These effects of age and
high blood pressure seem to be independent of each other [48].
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Plasma angiotensin II conc, pg/mi
Fig. 3. Vasodilator response to intraarterially infused verapamil(forearm venous occlusion plethysmography) related inversely to
plasma renin activity and angiotensin II concentration. (From Ref. 31.)
If this is so, then elderly hypertensive patients, following a
given degree of vasodilation, will have less counterregulatory
reflex activation and thereby less sympathetically mediated
vasoconstriction than will younger individuals and patients with
high-renin hypertension; the latter will have more reflex sym-
pathetic stimulation than will normotensive controls. Indirect
evidence is derived from the observation that normotensive
subjects have either no, or only a small, decrease of pressure
after administration of calcium antagonists [31, 49]. More direct
evidence comes from a study in which arterial baroreflex
sensitivity was related to the acute fall in blood pressure that
occurred after administration of sublingual nifedipine [50].
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Fig. 2. Intracellular free-calcium concentration in
platelets from normotensive and hypertensive
subjects as measured by the Quin 2 method (A)
and in parallel reduction with blood pressure
during calcium antagonist therapy (B). (Adapted
from Ref. 32.)
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Baroreflex sensitivity was inversely related to age, and subjects
with low sensitivities had the greatest acute falls in blood
pressure (Fig. 4). Also, subjects with the greatest increase in
plasma norepinephrine levels, a marker of changes of sympa-
thetic activity, had the greatest increase in cardiac output. This
nifedipine-induced hemodynamic response pattern tends to
counteract the decrease of pressure the most.
Similar responses suggestive of mild chronic sympathetic
stimulation have been observed with another dihydropyridine,
nitrendipine, in 18 patients [51]. In contrast, verapamil and
diltiazem do not cause either acute or chronic reflex stimula-
tion, as judged by plasma norepinephrine concentrations [52,
53]. Although plasma norepinephrine concentrations do not
accurately reflect sympathetic nervous system activity under all
circumstances [54, 55], and changes in heart rate cannot be
taken as indices of sympathetic activity because of these drugs'
direct negative chronotropic effects, these findings raise the
possibility that counterregulatory mechanisms differ between
the vasodilatory responses to dihydropyridines and verapamil
and diltiazem.
Other mechanisms probably also contribute to the antihyper-
tensive effects of calcium antagonists, but their quantitative
importance remains to be defined more precisely, Vasoconstric-
tion due to adrenergic stimulation is markedly reduced during
therapy, but it has been debated whether this inhibition applies
to both alpha- 1- and alpha-2-adrenoceptor-mediated vasocon-
striction [56—58]; the latter system is effectively blocked by
calcium antagonists [59]. Some interference with alpha-
1 -adrenoceptor-mediated vasoconstriction also seems likely,
however, because nifedipine lessens the degree to which the
alpha-i -adrenoceptor agonist phenylephrine increases blood
pressure in patients with hypertension [581. Although phenyl-
ephrine is not absolutely specific for the alpha- 1 type adreno-
ceptor, this and other findings [60] suggest an interference of
calcium antagonists with both alpha- 1- and alpha-2-adrenocep-
tor-mediated vasoconstriction (although the latter effect can be
more pronounced). Calcium antagonists also interfere with
angiotensin Il-mediated vasoconstriction [61] and return blood
pressure to normal in an animal model in which hypertension
was induced by continuous angiotensin II infusion [62]. Equally
important, calcium antagonists reduce angiotensin's stimula-
tory effect on aldosterone biosynthesis and secretion [63]. This
effect might be particularly pertinent when aldosterone is inap-
propriately high, for example, in low-renin essential hyperten-
sion [41].
Calcium antagonists: Cardiovascular counterregulation
The experience with calcium antagonists in the clinical inves-
tigation of hypertension has taught us an important lesson in
antihypertensive drug action. On the one hand, calcium antag-
onists eliminate excess calcium-influx-dependent vasoconstric-
tion and thereby tend to normalize elevated peripheral vascular
resistance, On the other hand, peripheral vasodilation is coun-
tered by baroreflex-induced sympathetic nervous system acti-
vation, which results in alpha-i- and alpha-2-adrenoceptor- and
angiotensin-mediated vasoconstriction (as well as cardiac and
renal stimulation). The more blunted the baroreflex, and the
beta-adrenoceptor and renin compensatory responses, the
greater the fall in blood pressure (see Fig. 1). At the level of the
vascular smooth muscle cell, calcium antagonists block slow-
channel calcium entry, but vascular contraction may be sus-
tained by release of superficial sarcoplasmic calcium; such
release could be mediated, for example, by an increase in
inositol triphosphate resulting from activation of alpha-i-
adrenoceptors or angiotensin receptors [64]. The existence of
such a counterregulatory phenomenon helps explain why a
combination of a calcium entry blocker and (renin suppressive)
beta blocker or angiotensin-converting-enzyme inhibitor is ef-
ficacious.
Unlike other vasodilating agents, calcium antagonists do not
cause sodium chloride and water retention. Indeed, no changes
in blood volume have been observed by us [13, 45} or others in
studies with nifedipine and verapamil [65, 66]. Accordingly, the
mechanism by which calcium antagonists lower blood pressure
without causing sodium retention awaits clarification.
Calcium antagonists: Renal effects
The dilatory effects of calcium antagonists on the renal
vasculature have been recognized for more than 25 years [1,
67], but the natriuretic effect (up to 10 g of negative sodium
chloride balance in the first few days of treatment) of nifedipine
and nitrendipine only recently has been appreciated [52, 68—70].
Whether verapamil is natriuretic is less clear; in some experi-
ments natriuresis or diuresis did not occur [52, 72], whereas in
others tubular sodium reabsorption fell [72].
Renal hemodynamic responses to calcium antagonists de-
pend greatly on the neural and hormonal determinants of renal
vascular tone; thus the hemodynamic responses to calcium
antagonists vary [73]. Their common and perhaps prominent
renal effects are reducing the degrees to which preglomerular
resistance is elevated, and maintaining or increasing glomerular
filtration rate [74—76]. These functions imply differential effects
on pre- and postglomerular resistance that sometimes can lead
to increases in the glomerular filtration rate.
Some nonvascular sites of calcium antagonist action seem to
contribute to natriuresis. Diminished tubular sodium reabsorp-
tion was found in the isolated perfused kidney [74—76] even
when renal plasma flow and GFR were kept constant [77]. A
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Fig. 4.Baroflex sensitivity decreases with the patient's age (insert), and
the acute (and chronic) antihypertensive effect of nifedipine is propor-
tional to this decrease. (Reprinted with permission from the American
College of Cardiology, ref. 50.)
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proximal tubular action is inferred by increased phosphate and
urate excretion after acute administration of calcium antago-
nists [78].
In humans, nitrendipine increased fractional sodium excre-
tion and free-water clearance during maximal water diuresis
[79]. This effect occurred without changes in renal plasma flow
or GFR, suggesting direct tubular action at a level proximal to
the diluting segment [79]. Distal tubular sodium reabsorption
was reduced in stop-flow studies [40, 77]. Although most of
these studies describe acute effects, the changes observed were
the opposite of those found with other vasodilating agents, such
as hydralazine and minoxidil, which acutely decrease sodium
and water excretion [72]. The new dihydropyridine, isradipine,
is natriuretic even with repetitive dosing, and the sodium
excretion rate and absolute proximal reabsorption correlate
(directly and indirectly, respectively) with the fall in blood
pressure [80].
Interference with aldosterone secretion [51, 61, 63] is yet
another factor by which calcium antagonists promote natriure-
sis. The slightly elevated aldosterone in low-renin essential
hypertension, in addition to the elevated preglomerular resis-
tance, might be the principal abnormalities on which calcium
antagonist action depends. The role of sodium-volume over-
filling in the antihypertensive mode of action of calcium antag-
onists is further supported by controlled studies showing that
calcium antagonists lower blood pressure more in patients on a
high sodium intake, both acutely [81—86] and chronically [87].
Renin, age, and race as indicators of antihypertensive
response
Beta blockers and converting enzyme inhibitors were more
effective in reducing blood pressure in the early phase of high
blood pressure in younger patients and in those with a high or
normal renin ("normal" still being too high for the elevated
pressure), than in older patients or those with low-renin hyper-
tension [88]. In approximately 80% of patients under the age of
40 years, a beta blocker [891 or converting enzyme inhibitor [90]
will return the diastolic blood pressure to normal, that is, below
95 mm Hg. The response rate in the age group between 40 and
60 years is about 50%; an age relationship with beta blocker
monotherapy was found in this subgroup as well [91]. In
patients over the age of 60 years, beta blockers or converting
enzyme inhibitors normalize blood pressure in about 20% of
patients; combination therapy is required in the remainder. A
similar picture emerges for the renin subgroups with a response
rate to beta blockers of about 80% in high-, 50% in normal-, and
20% in low-renin essential hypertension (Fig. 5). These re-
sponse rates are comparable to those found with converting
enzyme inhibitors [92]. Although such an age- and renin-related
response pattern has not been found in every study of beta
blockers or converting enzyme inhibitors a substantial body of
supportive information has come from investigators around the
world [93].
Diuretic drugs are more effective than are beta blockers in
older patients, many of whom exhibit a low renin level. Blood
pressure normalization with diuretics has been interpreted as
normalization of pretreatment volume overfilling [94, 951. In
addition to a modest elevation of cardiopulmonary volume [42],
two other important cardiovascular parameters characterize
older patients and those with low-renin hypertension: increased
calcium influx-dependent vasoconstriction and blunted cardio-
vascular reflex regulation. The blood pressure response pattern
to calcium antagonists is similar to that seen with diuretics [13].
Calcium antagonists normalize blood pressure in about 80% of
patients older than 60 years and in those with a low renin level
(Fig. 5), in 50% of those between the ages of 40 and 60 years and
in those with normal renin level, and in only about 20% of
patients under the age of 40 years and in those with a high renin
level [13, 96—98]. More recent studies are in keeping with this
view [99—109]. Using calcium antagonists in a slow-release form
[110] or employing the newer, longer-acting dihydropyridines
(such as nitrendipine [97] or amlodipine [1111) could simplify
antihypertensive care as much as current practice with diuret-
ics.
Low-renin hypertension is common in black hypertensive
patients. For this reason, diuretics have been used as first-
choice therapy [112, 113]. Beta blockers [1141 and converting
enzyme inhibitors [115] are less effective in black than in white
patients. As a new alternative to diuretics, calcium antagonists
have proven most efficacious in black hypertensives. In a recent
double-blind, randomized comparison with atenolol, an age
relationship in blacks also was observed [102].
Why is it that a renin, age, or race relationship is not found in
all trials? There seem to be some common problems with drug
testing relative to these predictors. The impacts of these pre-
dictors, although highly significant, are not overwhelmingly
strong. Analyses of these predictors have helped in the design
of treatment strategies, but they are not mandatory criteria for
drug selection in an individual patient. Correlations between
such predictors and antihypertensive response usually are
found only with study populations of several dozens and in
studies with a high degree of standardization. Daytime varia-
tion, quality of blood pressure recording, renin assay variabil-
ity, and recognition of drug kinetics and dose adjustment are
important. For these reasons multicenter trials in data collec-
tion often fail to show these relationships in spite of a large
study population.
Age in years Renin-sodium index
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Fig. 5. In younger (left) and high-renin (right) patients, normalization of
blood pressure (95 mm Hg diastolic) occurs more often with beta
blockers (upper panel) titan with calcium antagonists (lower panel); in
older patients and in those with lower plasma-renin activity, the reverse
is true. (Adapted from Ref. 88.)
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Effective drug combinations for severe and renal
hypertension
Even though factors such as age, renin, and race help one in
selecting an appropriate drug, about 20% of patients require
drug combinations to achieve a diastolic pressure of 95 mm Hg
or below; 30% of patients require combination therapy if the
new WHL/WHO/ISH recommendation of 90 mm Hg [1161 is
applied. The quality of blood pressure control is the first aim of
antihypertensive therapy. More reasonable, effective, and usu-
ally better tolerated drug combinations are available, however,
and the pathophysiologic considerations I have mentioned can
help in determining which of these combinations is the most
appropriate. It is of little benefit to combine a beta blocker with
a converting enzyme inhibitor or a calcium antagonist with a
diuretic [117], but alternate combinations are highly effective,
particularly in patients with severe hypertension [118, 1191.
Thus, calcium antagonists of the dihydropyridine type can be
safely combined with beta blockers [113, 1191, but both vera-
pamil and diltiazem should be added only after great caution
and consideration of contraindications such as sick-sinus syn-
drome, atrioventricular conduction defects, or impaired cardiac
contractility [1181. All of the calcium antagonists can be most
effectively and safely combined with converting enzyme inhib-
itors; this drug combination is preferred in patients with refrac-
tory hypertension [119]. It may well be that the deterioration of
renal function associated with converting enzyme inhibitors in
bilateral renovascular hypertension can be prevented by their
combination with calcium antagonists. Combinations of dif-
ferent calcium antagonists may have additive effects, but like
their combination with diuretics, there is little gain in blood
pressure control. Although in patients with essential hyperten-
sion, blood pressure control rarely necessitates the use of a
diuretic, no strong argument can be made against the addition of
diuretics (providing these agents have a potassium-sparing
component and are administered in a low dose); the notion that
diuretics can cause excessive cardiovascular morbidity or mor-
tality [1201 has been contradicted by recent large trials (the
IPPPSH [121], MRC trial in mild hypertension [122], EPWHY
[123], HAPPHY [1241, and MAPHY [1251). Some beta blockers
might afford a special benefit [121, 122, 125], particularly in men
who do not smoke [121, 1221.
In patients with hypertension secondary to renal parenchy-
mal disease, calcium antagonists were most efficacious [85],
possibly because of the relative volume expansion and low
renin status often seen in these patients. However, as renal
function is reduced, more patients treated with calcium antag-
onists seem to benefit from the addition of a diuretic agent [1261.
Whether long-term calcium antagonist therapy has a beneficial
effect on renal function is still unknown.
Does calcium antagonist therapy preserve organ function?
Experimental evidence strongly suggests that calcium antag-
onists enhance tissue perfusion and provide a protective effect
on different tissues, such as myocardium [127] and vasculature
(including a delaying effect on the development of arterioscle-
rosis [128]). In the clinical setting, however, these effects have
not been proven. Several efforts have failed to demonstrate that
calcium antagonist therapy reduces cardiac death or reinfarc-
tion following a myocardial infarction [129], except for recent
studies with diltiazem [130, 131]. These results point to possible
differences among the three major types of calcium antagonists,
in which the balance between the potential tissue protection and
the drug-induced fall in coronary, or perhaps also cerebrovas-
cular, perfusion pressure might be crucial.
Similarly, calcium antagonists have been used in an attempt
to maintain GFR and to prevent renal damage and the renal
inflammatory response to injury. For example, glomerular
damage in experimental glomerulonephritis can be reduced by
various calcium antagonists [132, 133]. Prostaglandin-induced
reduction in glomerular filtration consequent to preglomerular
vasoconstriction has been reversed by diltiazem [134]. Radio-
contrast medium-induced renal insufficiency has been attenu-
ated with simultaneous administration of a calcium antagonist
[135]. More recently, the claim has been made that calcium
antagonists reduce or prevent the development of hypertension
in renal transplant patients treated with the immunosuppressant
cyclosporine A [1361. We need to better understand (low-dose)
cyclosporine-induced renal damage and hypertension, in which
endothelium-related relaxation is blunted [137]. Further, an
elucidation of the mode of calcium antagonist action might help
explain new pathophysiologic mechanisms in hypertension.
Questions and answers
DR. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): In
view of the fact that decreased cytolic calcium concentration is
an intense stimulus to renin secretion, what mechanisms might
mediate the maintenance of plasma renin activity at its basal
level during chronic treatment with calcium channel blockers?
PROF. BUHLER: This is a good point. First of all, the fact that
renin does not rise might be due to blunted counterregulation;
apparently, there is not much of a sympathetic counterregula-
tion to stimulate renin release during treatment with calcium
antagonists, unlike the case of treatment with hydralazine or
minoxidil. The second reason might be the opposite effect
calcium has on renin release. Because increased calcium con-
centration causes renin suppression, a reduction in cytosolic
calcium concentration produces in fact relative renin stimula-
tion. Thus, these factors might cancel out the effect of blood
pressure reduction thereby maintaining renin secretion more or
less unchanged.
PROF. EBERHARD RITZ (Department of Internal Medicine,
University of Heidelberg, Heidelberg, Federal Republic of
Germany): You mentioned that calcium blockers induce pref-
erential afferent arteriolar dilation at the glomerular level. With
respect to intrarenal hemodynamics, this is exactly the change
that will be disadvantageous for the patient with pre-existing
renal disease. How do you see the role of calcium antagonists in
patients with chronic renal insufficiency?
PROF. BUHLER: Experimental studies indicate that the main
effect of calcium antagonists in renal hemodynamics is clearly
on the afferent arteriole, yet to a lesser extent efferent arteriolar
dilation also is effected. Such patterns would be expected to
lead to increased glomerular filtration rate and augmented
proximal sodium delivery and reabsorption. This effect, how-
ever, is countered by two factors: first, a proximal tubular effect
of calcium antagonists by which sodium reabsorption is inhib-
ited, and second, a suppressive effect on aldosterone secretion
that leads to decreased distal sodium reabsorption. I understand
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that on theoretical grounds the resultant increased intraglomer-
ular pressure should be expected to exert untoward effects on
renal function. Nevertheless, the balance of the available data
do not suggest that long-term treatment with calcium antago-
nists leads to deterioration in renal function. On the other hand,
some data suggest that calcium antagonists blunt cyclosporine
A-induced hypertension in renal transplant patients and that
these agents lessen proteinuria [1361. In my opinion, much more
experience is needed before the long-term effects of these
agents on renal function can be appraised.
PROF. L. A. VAN Es (Chief, Department of Nephrology,
Leiden University, Leiden, The Netherlands): Have measure-
ments of the filtration fraction been carried out in hypertensive
patients before and after treatment with calcium channel block-
ers?
PROF. BUHLER: In theory, one would anticipate that the
already increased filtration fraction of hypertensive patients
would increase further following treatment with calcium antag-
onists. However, increases and decreases both have been
obtained in clinical studies.
DR. JEROME P. KASSIRER (Associate Physician-in-Chief, De-
partment of Medicine, New England Medical Center): Would
you comment on the relation between dietary calcium intake
and hypertension, or the relation between sodium intake and
hypertension? How does dietary calcium or sodium intake
influence the response to calcium-channel blockers?
PROF. BUHLER: I must say that I do not feel particularly
comfortable with this kind of mental exercise. My own view is
that the data are simply not there to indicate that ingestion of
more calcium will lower blood pressure, and I consider the idea
of a central role of dietary calcium in the pathogenesis of
hypertension as a gross oversimplification of the issue. On the
other hand, there is substantial support in the literature for the
concept that more sodium makes the calcium antagonist more
effective. This is clearly shown in the work of Drs. Nicholson,
Laragh, and Resnick, in which the effectiveness of the calcium
antagonist was augmented when patients on a normal sodium
diet were given a higher sodium intake [138]. This finding is in
keeping with the concept that the slightly volume-expanded,
older low-renin patients are more responsive to calcium antag-
onism and that one must not reduce sodium intake in these
patients. The fact that treatment of hypertension with calcium
antagonists does not require imposition of a sodium-restricted
diet is a clear therapeutic advantage.
DR. MADIAS: Has the age-related differential responsiveness
to calcium-channel blockers been tested at similar doses of
medication? Has the possibility that the elderly might handle
these agents differently been tested? That is, has the possibility
of increased bioavailability been considered?
PROF. BUHLER: Yes, in fact it has been shown for all three
types of calcium antagonists that bioavailability increases
slightly with age. This minor effect—better bioavailability in the
elderly—probably has been balanced, however, by the fact that
younger individuals have been treated more aggressively and
therefore have been given excessive amounts of calcium antag-
onists; yet younger individuals have not responded equally
well.
DR. JORDAN J. COHEN (Dean of Medicine, State University
of New York at Stony Brook, Stony Brook, New York): Have
the calcium antagonists been available for a sufficient period to
confirm the age dependency in blood pressure response by
long-term cohort studies?
PROF. BUHLER: I wonder whether the cohort-study approach
is the right one for studying a biologic effect that is confounded
by so many factors. I think that the answer should be provided
by double-blind, controlled, randomized trials, Approximately
20 studies that are open, including our own, have found this
age-related effect.
DR. COHEN: With respect to the pathogenetic role of intra-
cellular calcium in essential hypertension, have studies demon-
strated that abnormalities in calcium metabolism antedate the
elevated blood pressure in humans?
PROF. BUHLER: So far, we have not been able to show
elevated intracellular calcium concentration in "prehyperten-
sive" subjects, that is, in the offspring of hypertensive patients.
Of course, the existing derangement at that stage might be
beyond the resolution of current methods. I think the question
of defects in calcium homeostasis even before blood pressure
starts to rise remains open.
DR. MADIA5: Regarding the persistent hyperresponsiveness
of platelet cytosolic calcium to adrenaline that you have shown
in treated hypertensive patients [32], does the mode or duration
of treatment influence this response?
PROF. BUHLER: These studies have been carried out in only
a small group of patients; treatment modalities included beta-
blockers and calcium antagonists, and no difference between
the two could be discerned. I should add that for adrenaline to
demonstrate this effect, prestimulation of platelets with throm-
bin is required.
PROF. CHARLES VAN YPERSELE (Professor of Medicine,
University of Louvain Medical School, Hôpital St. Luc, Brus-
sels, Belgium): To go back to Dr. Cohen's question on genetic
factors in hypertension, is there any relationship between
sodium transport abnormalities in red blood cells or leukocytes
and abnormalities in cytosolic calcium or in intracellular calci-
um-binding proteins?
PROF. BUHLER: In accordance with the hypothesis of
Blaustein and others [14], there might be a relationship between
inhibition of Na ,K ATPase activity and reduction in sodium!
calcium exchange that results in increased cytosolic calcium
concentration. The problem with this hypothesis rests with the
timing of the inhibition of the Na,K ATPase. Does it happen
early or late in the course of hypertension? There is absolutely
no evidence so far, in animals or humans, that in early hyper-
tension Na ,K ATPase activity is blunted. Whenever the
defect has been described, it has occurred later in the course of
the disease. Moreover, the putative circulating factor that
inhibits Na,K ATPase in the kidney and other tissues is
thought to be released from the pituitary gland in response to
volume expansion. I know of not a single example in which
extracellular fluid volume is expanded in the early phase of
hypertension. Thus, there are several problems with this entire
hypothesis, including the trigger mechanism and the circulating
inhibitor itself, which remains unidentified. It appears far more
probable that this mechanism, if it exists at all, is secondary to
another abnormality of the hypertensive process. The argument
might be totally different when one focuses on other pump
mechanisms, such as the sodium/calcium exchanger or the
sodium/hydrogen antiporter.
DR. MADIAS: Is the natriuresis of calcium-channel blockers
302 Nephrology Forum: Calcium antagonists in low-renin hypertension
accompanied by other cationic losses, such as potassium,
calcium, or magnesium?
PROF. BUHLER: To my knowledge, the natriuresis is unac-
companied by losses of other cations.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): Could you com-
ment on the effects of calcium-channel blockers on tissues other
than platelets and vascular smooth muscle? What accounts for
the fact that these agents have little or no effect on tissues such
as striated muscle?
PROF. BUHLER: I think that it is only a miracle that the
calcium antagonists seem to have preferential affinity for cal-
cium channels in the cardiovascular system. Although I do not
wish to talk about calcium channels of the heart in detail,
inhibition of these channels causes a reduction in left-ventric-
ular hypertrophy very much like that induced by beta blockade,
alpha blockade, or converting enzyme inhibition, but unlike
that produced by diuretic therapy. Clearly, calcium channels
have an effect on the heart over and above the afterload-
reducing effect. It remains unclear, however, why the calcium
antagonists do not affect striated muscle or attack bone. It is a
well-studied fact that chronic, long-term antihypertensive or
antianginal therapy does not affect bone metabolism, but why
this is so is not clear. These channels probably have different
affinities, work at different electric potentials, or have different
accessibilities compared with those of the cardiovascular sys-
tem. In fact, what we now call tissue or organ selectivity might
be merely a physical consequence of variable abilities of
calcium antagonists to diffuse to membranes rather than the
result of a differential distribution of receptor sites.
PROF. YVES PIRs0N (Department of Nephrology, Cliniques
Universitaires St. Luc, Brussels, Belgium): Do you think that
calcium antagonists should be first-line treatment of hyperten-
sion induced by cyclosporine?
PROF. BUHLER: There is clear evidence that calcium antago-
nists attenuate cyclosporine A-induced aggregability of plate-
lets. No indication exists that calcium antagonists might in-
crease the nephrotoxicity of cyclosporine A. In fact, studies on
small numbers of patients suggest that calcium antagonists
reduce or prevent the development of hypertension in renal
transplant recipients treated with cyclosporine A and that these
agents also reduce proteinuria [1361. This issue, as well as the
impact of calcium antagonists on renal function, should be
examined in a well-designed, large-scale trial. Calcium antago-
nists might well be the treatment of choice for cyclosporine
A-induced hypertension, although the pathogenesis of this
entity remains unknown. Recent work from our laboratory
suggests, however, that reduction of endothelium-derived re-
laxing factor might be a key event in the development of this
form of hypertension [137].
DR. COHEN: You suggested that calcium-channel blockers
might protect patients with bilateral renal artery stenosis from
the acute deterioration in renal function produced by converting
enzyme inhibitors. What might be the basis for such an effect?
PROF. BURLER: Limited data suggest that the combination of
these two agents indeed might be advantageous for maintaining
renal function in this setting. Although I am not certain that I
fully understand this interaction, it might be that inhibition of
the angiotensin-Il effect on the efferent arteriole by converting
enzyme inhibitors is not the sole explanation for the adverse
effect of these agents on renal function in bilateral renal artery
stenosis (or the beneficial effect in renal parenchymal disease).
There also might be a tubuloglomerular effect at play, and I
consider it likely that calcium antagonists act by interfering with
this effect.
Reprint requests to Prof. F. Buhler, Division of Cardiology, Univer-
sity Hospital, 4031 Basel, Switzerland
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